Last reviewed · How we verify
OLA group: Olanzapine
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Agitation associated with schizophrenia and bipolar disorder.
At a glance
| Generic name | OLA group: Olanzapine |
|---|---|
| Also known as | Steroid-sparing therapy |
| Sponsor | The Guthrie Clinic |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing psychotic symptoms, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. It also has activity at multiple other receptors including muscarinic, histamine H1, and alpha-adrenergic receptors, contributing to its side effect profile.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Agitation associated with schizophrenia and bipolar disorder
Common side effects
- Weight gain
- Sedation
- Dizziness
- Akathisia
- Hyperglycemia/diabetes risk
- Hyperlipidemia
- Prolactin elevation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OLA group: Olanzapine CI brief — competitive landscape report
- OLA group: Olanzapine updates RSS · CI watch RSS
- The Guthrie Clinic portfolio CI